Previous close | 14.06 |
Open | 13.95 |
Bid | 13.86 x 4000 |
Ask | 14.00 x 4000 |
Day's range | 13.85 - 14.02 |
52-week range | 13.05 - 17.31 |
Volume | |
Avg. volume | 2,702,567 |
Market cap | 43.041B |
Beta (5Y monthly) | 0.90 |
PE ratio (TTM) | 25.67 |
EPS (TTM) | 0.54 |
Earnings date | N/A |
Forward dividend & yield | 0.80 (5.71%) |
Ex-dividend date | 29 Sept 2021 |
1y target est | 19.22 |
OSAKA, Japan & PASADENA, Calif., June 27, 2022--Results from Phase 2 Study of fazirsiran in patients with alpha-1 antitrypsin deficiency published in New England Journal of Medicine.
CAMBRIDGE, Mass., June 22, 2022--Takeda (TSE:4502/NYSE:TAK) today announced that it has signed a 15-year lease with BioMed Realty for approximately 600,000 square feet of research and development (R&D) and office space to be built at 585 Third Street in Kendall Square. The state-of-the-art facility will allow Takeda, the largest life sciences employer in Massachusetts, to create a purpose-built R&D facility with laboratories of the future featuring modern design elements and upgraded technology
Dividend stocks are just as prone as other stocks to underperforming the market and doing pretty much everything except what you want them to do -- increase and pay out. The catch is that some of the worst dividend investing mistakes are disguised as being juicy opportunities. Let's go over three of the most tempting and most destructive foibles so that you'll be protected against them when you're figuring out which passive income stocks are worth your money.